Fellowships

• H Lee Moffit Cancer Ctr & Research Inst @ Usf, 2021, Oncology and Hematology
• H Lee Moffit Cancer Ctr & Research Inst @ Usf, 2022, Bone Marrow Transplant

Residency

• Wake Forest University, 2018

Medical Education

• Boston University, 2015

Certifications

• American Board of Internal Medicine-Hematology
• American Board of Internal Medicine-Internal Medicine

Publications

Professional Organizations

• American Society for Apheresis
• American Society for Transplantation and Cellular Therapy
• American Society of Clinical Oncology
• American Society of Hematology
• Florida Society of Clinical Oncology
• Society for Immunotherapy of Cancer

Presentations

• Hansen DK, Peres L, Freeman C, et al. (February, 2023). Baseline Levels of Systemic Inflammatory Markers Interleukin 6 and Ferritin Are Associated with Toxicities and Progression-Free Survival in Multiple Myeloma Patients Treated with Idecabtagene Vicleucel. Tandem Meetings of ASTCT and CIBMTR; Orlando, FL, USA.
  
  
• Ionescu F, Freeman C, Castaneda O, et al. (February, 2023). Fludarabine Exposure Impact on Safety and Efficacy of Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma (RRMM). Tandem Meetings of ASTCT and CIBMTR; Orlando, FL, USA.
  
  
• Mohty R, Drekolias D, Peres L, et al. (February, 2023). Hematopoietic Recovery after Anti-B Cell Maturation Antigen (BCMA) Chimeric Antigen Receptor T Cell Therapy (CAR T), Idecabtagene Vicleucel (Ide-cel), for Relapsed/Refractory Multiple Myeloma (RRMM). Tandem Meetings of ASTCT and CIBMTR; Orlando, FL, USA.
  
  
• Rejeski K, Hansen DK, Bansal R, et al. (December, 2022). The CAR-Hematotox Score as a Prognostic Model of Toxicity and Response in Patients Receiving BCMA-Directed CAR-T for Relapsed/Refractory Multiple Myeloma. Annual Meeting of the American Society of Hematology; New Orleans, LA, USA.
  
  
• Jim HSL, Hoogland AI, Logue JL, et al. (December, 2022). Real-World Patient-Reported Outcomes Among Recipients of Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell Lymphoma. Annual Meeting of the American Society of Hematology; New Orleans, LA, USA.
  
  
• Logue JM, Shrewsbury AM, Peres LC, et al. (May, 2022). Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma. Moffitt Scientific Symposium; Tampa, FL, USA.
  
  
• Logue JM, Shrewsbury AM, Peres LC, et al. (April, 2022). Cytopenia and Infection Early after Standard of Care Idecabtagene Vicleucel in Multiple Myeloma. Tandem Meetings of ASTCT and CIBMTR; Salt Lake City, UT, USA.
  
  
• Hansen DK, Shrewsbury AM, Peres L, et al. (April, 2022). Marrow Myeloma Burden and Idecabtagene Vicleucel Outcomes in the Standard of Care Setting. Tandem Meetings of ASTCT and CIBMTR; Salt Lake City, UT, USA.
  
  
• Hansen DK, Shrewsbury AM, Peres L, et al. (April, 2022). Impact of Obesity on Lymphodepletion and Outcomes Following Idecabtagene Vicleucel. Tandem Meetings of ASTCT and CIBMTR; Salt Lake City, UT, USA.
  
  
• Barata A, Hoogland AI, Kommalapati A, Logue J, Hyland K, Eisel SL, Small BJ, Welniak T, Irizarry-Arroyo N, Rodriguez Y, Jayani RV, Booth-Jones M, Oswald LB, Gonzalez BD, Kirtane KS, Jain MD, Mohktari S, Chavez JC, Lazaryan A, Shah BD, Locke FL, Jim SLH. (December, 2021). Change in Patients’ Perceived Cognition Among Chimeric Antigen Receptor T-Cell Therapy Recipients at Day 360. Annual Meeting of the American Society of Hematology; Atlanta, GA, USA.
  
  
• Logue JM, Shrestha B, Hendricks J, Diaz-Rijo J, Yu B, Kroeger J, Zhang S, Cubitt C, Davila ML. (May, 2020). Identification of immune targets for development of a multi-antigen T cell therapy for AML. Moffitt Scientific Symposium; Tampa, FL, USA.
  
  
• Logue JM, Krivenki GS, Larson V, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Lazaryan A, Liu HD, Pinilla-Ibarz J, Shah BD, Dholaria BR, Jain MD, Locke FL. (May, 2019). Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL). American Society of Clinical Oncology; Published online via Journal of Clinical Oncology 37(15).
  
  
• Logue JM, Krivenki GS, Larson V, Bachmeier CA, Chavez JC, Davila ML, Khimani F, Lazaryan A, Liu HD, Pinilla-Ibarz J, Shah BD, Dholaria BR, Jain MD, Locke FL. (May, 2019). Cytopenia following axicabtagene ciloleucel (axi-cel) for refractory large B-cell lymphoma (LBCL). Moffitt Scientific Symposium; Tampa, FL, USA.
  
  
• Logue JM, Qasem S, Miller L, Watabe K, Su J, Laxton AW, Tatter SB, Chan MD, Ruiz J. (May, 2017). A Genetic Signature for Predicting Brain Metastasis Recurrence after Stereotactic Radiosurgery. Wake Forest Department of Internal Medicine Research Symposium; Winston Salem, NC, USA.
  
  
• Batt K, Logue JM, Imboden L, Smith A, Bonomi M. (May, 2017). Eradicating an Old Inhibitor: Elimination of a Factor VIII inhibitor in a Patient with Hemophilia A. Wake Forest Department of Internal Medicine Research Symposium; Winston Salem, NC, USA.
  
  
• Logue JM, Qasem S, Miller L, Watabe K, Su J, Laxton AW, Tatter SB, Chan MD, Ruiz, J. (February, 2017). A Genetic Signature for Predicting Brain Metastasis Recurrence after Stereotactic Radiosurgery. American College of Physicians North Carolina Annual Chapter Scientific Meeting; Durham, NC, USA.
  
  
• Logue JM, Qureshi MM, Zaner KS, Cooley TP, Jalisi S, Truong MT. (September, 2013). The Evaluation of Chemoradiotherapy Toxicity and Outcome in Head and Neck Cancer. American Society for Radiation Oncology; Atlanta, GA, USA.
  
  
• Logue JM, Qureshi MM, Zaner KS, Cooley TP, Jalisi S, Truong MT. (February, 2013). The Evaluation of Chemoradiotherapy Toxicity and Outcome in Head and Neck Cancer. Medical Student Summer Research Symposium; Boston, MA, USA.
  
  
• Logue JM, Demarco RS, Lundquist EA. (April, 2011). Protein Kinase C interacts with Rac GTPases in the control of the actin-binding protein UNC-115/abLIM in Caenorhabditis elegans axon pathfinding. University of Kansas Undergraduate Research Symposium; Lawrence, KS, USA.
  
  
• Logue JM, Ahn Y, Krumlauf R. (July, 2010). Function of Wise/Sostdc1 in murine mammary gland development. Stowers